论文部分内容阅读
目的:探讨Her-2/neu表达及临床病理特征对无淋巴结转移的早期胃癌患者预后的影响。方法:收集70例有完整随访记录和病理组织蜡块保存完整的无淋巴结转移的早期胃癌根治手术切除患者资料,采用免疫组化法检测病理组织切片Her-2/neu表达情况,分析Her-2/neu表达及临床病理因素与患者预后的关系。结果:全组Her-2/neu阳性表达率为25.0%,Her-2/neu表达与患者的性别、年龄、肿瘤大小、分化类型及浸润深度均无明显关系(均P>0.05)。全组5年生存率为87.8%。单因素分析显示,患者性别、年龄、肿瘤大小、肿瘤浸润深度及分化程度对患者生存状况无明显影响(均P>0.05)。Her-2/neu表达阳性患者的5年生存率72.0%,阴性患者为93.0%,差异有统计学意义(P<0.05)。多因素回归分析显示,Her-2/neu的表达为影响预后的危险因素(OR=5.036,P=0.035)。结论:Her-2/neu的表达是影响无淋巴结转移早期胃癌患者预后的危险因素,并对早期胃癌的临床治疗有一定指导意义。
Objective: To investigate the effect of Her-2 / neu expression and clinicopathological features on the prognosis of patients with early gastric cancer without lymph node metastasis. Methods: The data of 70 cases of radical resection of gastric cancer with complete follow-up records and complete preservation of pathological tissue without lymph node metastasis were collected. The expression of Her-2 / neu in pathological sections was detected by immunohistochemistry. / neu expression and clinicopathological factors and prognosis of patients. Results: The positive expression rate of Her-2 / neu in the whole group was 25.0%. The expression of Her-2 / neu had no significant correlation with the gender, age, tumor size, differentiation type and depth of invasion (all P> 0.05). The 5-year overall survival rate was 87.8%. Univariate analysis showed that the patient’s gender, age, tumor size, depth of tumor invasion and differentiation had no significant effect on the survival of patients (all P> 0.05). The 5-year survival rate was 72.0% in Her-2 / neu positive patients and 93.0% in negative patients, the difference was statistically significant (P <0.05). Multivariate regression analysis showed that the expression of Her-2 / neu was a risk factor for prognosis (OR = 5.036, P = 0.035). Conclusion: The expression of Her-2 / neu is a risk factor affecting the prognosis of patients with early stage gastric cancer without lymph node metastasis and is of guiding significance to the clinical treatment of early gastric cancer.